Oncternal Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization medicines to treat medical conditions, including stress urinary incontinence and prostate cancer. Co. is focused on the further development of selective androgen receptor modulators (SARMs), including its primary product candidate, enobosarm (GTx-024). SARMs is a class of drugs that has the potential to treat serious medical conditions such as stress urinary incontinence. Co. is also evaluating enobosarm and other compounds in its SARM portfolio for indications outside of oncology. The GTXI average annual return 10 years is shown above.
The Average Annual Return on the GTXI average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether GTXI average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GTXI average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Video: Don't Forget Dividends in Average Annual Return!
